AR089797A1 - Vacunas contra clostridum difficile que comprenden toxinas recombinantes - Google Patents

Vacunas contra clostridum difficile que comprenden toxinas recombinantes

Info

Publication number
AR089797A1
AR089797A1 ARP130100216A ARP130100216A AR089797A1 AR 089797 A1 AR089797 A1 AR 089797A1 AR P130100216 A ARP130100216 A AR P130100216A AR P130100216 A ARP130100216 A AR P130100216A AR 089797 A1 AR089797 A1 AR 089797A1
Authority
AR
Argentina
Prior art keywords
toxin
toxins
recombinant
difficile
refers
Prior art date
Application number
ARP130100216A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Intervet Int Bv filed Critical Merck Sharp & Dohme
Publication of AR089797A1 publication Critical patent/AR089797A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente se refiere a la toxina proteica A (TcdA) y a la toxina proteica B (TcdB) y a la toxina proteica binaria A (CDTa) de C. difficile recombinantes que comprenden mutaciones definidas específicamente con respecto a la secuencia de las toxinas nativas que reducen sustancialmente o eliminan la toxicidad. También se refiere a vacunas y a composiciones inmunógenas que comprenden estas toxinas recombinantes, así como a combinaciones de estas toxinas con la toxina binaria B (CDTb), que pueden ofrecer protección contra la infección provocada por C. difficile y/o los efectos de la misma. También se refiere a procedimientos para inducir una respuesta inmune contra C. difficile que comprenden administrar las vacunas y las composiciones inmunógenas descritas en la presente memoria a un paciente. También engloba procedimientos de expresión de mutantes de la toxina A. la toxina B y CDTa de C. difficile recombinantes, y CDTb en sistemas de expresión recombinantes. En realizaciones ejemplares, las toxinas mutantes TcdA, TcdB y CDTa que comprenden suficientes mutaciones para reducir sustancialmente o eliminar la toxicidad se expresan en el sistema de expresión de baculovirus/células de insecto. Ácido nucleico, vector y célula huésped. Procedimiento para producir la proteína.
ARP130100216A 2012-01-27 2013-01-24 Vacunas contra clostridum difficile que comprenden toxinas recombinantes AR089797A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591631P 2012-01-27 2012-01-27
US201261596419P 2012-02-08 2012-02-08
US201261703754P 2012-09-20 2012-09-20

Publications (1)

Publication Number Publication Date
AR089797A1 true AR089797A1 (es) 2014-09-17

Family

ID=48873956

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100216A AR089797A1 (es) 2012-01-27 2013-01-24 Vacunas contra clostridum difficile que comprenden toxinas recombinantes

Country Status (14)

Country Link
US (1) US9388394B2 (es)
EP (1) EP2807186A4 (es)
JP (2) JP2015506948A (es)
KR (1) KR20140117433A (es)
CN (1) CN104039816B (es)
AR (1) AR089797A1 (es)
AU (1) AU2013211973B2 (es)
BR (1) BR112014018432A8 (es)
CA (1) CA2856443A1 (es)
IN (1) IN2014CN04187A (es)
MX (1) MX351074B (es)
RU (1) RU2014134365A (es)
TW (1) TW201335178A (es)
WO (1) WO2013112867A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111647059B (zh) 2011-04-22 2023-11-28 惠氏有限责任公司 涉及突变体难辨梭菌毒素的组合物及其方法
US9694063B2 (en) * 2011-12-08 2017-07-04 Glaxosmithkline Biologicals Sa Clostridium difficile toxin-based vaccine
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
EP2988778A4 (en) * 2013-04-22 2016-12-14 Board Of Regents Of The Univ Of Oklahoma CLOSTRIDIUM DIFFICILE IMPREGENT AND METHOD OF USE
WO2014197651A1 (en) * 2013-06-05 2014-12-11 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
CN105611942A (zh) 2013-06-14 2016-05-25 圣诺菲·帕斯图尔公司 针对艰难梭菌免疫的组合物和方法
EP3160500B1 (en) 2014-06-25 2019-08-21 GlaxoSmithKline Biologicals S.A. Clostridium difficile immunogenic composition
JP2017212882A (ja) * 2014-10-10 2017-12-07 学校法人 名城大学 アセチルエステラーゼ及びその利用
JP2018521967A (ja) 2015-05-15 2018-08-09 サノフィ パストゥール インコーポレイテッド クロストリジウム・ディフィシルに対する免疫方法
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
RU2761249C2 (ru) * 2016-12-14 2021-12-06 Мерк Шарп энд Доум Корп. Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile
US10668140B2 (en) 2017-02-24 2020-06-02 University Of South Floirida Non-toxigenic Clostridium difficile spores for use in oral vaccination
AU2018236352B2 (en) 2017-03-15 2024-04-04 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
US10555992B2 (en) 2017-05-31 2020-02-11 University Of South Florida Immunogenic proteins against clostridium difficile
CA3064357A1 (en) 2017-06-09 2018-12-13 Hipra Scientific, S.L.U. Vaccine comprising clostridium toxoids
WO2018233813A1 (en) 2017-06-20 2018-12-27 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM TOXINS WITH INCREASED DURATION
WO2019007509A1 (en) 2017-07-06 2019-01-10 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM NEUROTOXINS WITH INCREASED DURATION
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
US20200123210A1 (en) * 2018-10-17 2020-04-23 Eternity Biomedical Laboratories, Inc. Immunogenic preparations and methods against clostridium difficile infection
CN110041437B (zh) * 2019-04-29 2020-12-25 中国兽医药品监察所 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白
CN110607314B (zh) * 2019-10-31 2022-09-23 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
CN112442472B (zh) * 2020-11-30 2023-05-26 四川大学华西医院 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法
WO2023143559A1 (en) * 2022-01-30 2023-08-03 Westlake University Tfpi binding polypeptides and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
CA2307331C (en) 1997-10-20 2017-03-21 Oravax, Inc. Passive immunization against clostridium difficile disease
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
AU2003299527A1 (en) 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
WO2005060377A2 (en) 2003-12-08 2005-07-07 Hybridon, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
US7625559B2 (en) 2004-02-06 2009-12-01 University Of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
KR101149687B1 (ko) * 2006-03-30 2012-05-25 엠브렉스, 인코포레이티드 가금류의 예방접종 방법 및 조성물
AU2010213708B2 (en) 2009-02-11 2015-12-10 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
CA2752815A1 (en) * 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
JP2013503198A (ja) 2009-08-27 2013-01-31 シナプティック リサーチ，リミテッド ライアビリティ カンパニー 人工多能性幹（ｉＰＳ）細胞または組織特異的細胞を誘導するための新規タンパク質送達系
US10046040B2 (en) 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
CA2782406A1 (en) * 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
AU2011298306B2 (en) 2010-09-03 2017-10-19 Valneva Austria Gmbh Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
US8431361B2 (en) * 2010-09-17 2013-04-30 Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B
CN111647059B (zh) * 2011-04-22 2023-11-28 惠氏有限责任公司 涉及突变体难辨梭菌毒素的组合物及其方法

Also Published As

Publication number Publication date
KR20140117433A (ko) 2014-10-07
CA2856443A1 (en) 2013-08-01
CN104039816B (zh) 2018-02-09
AU2013211973B2 (en) 2017-10-12
BR112014018432A2 (es) 2017-06-20
US20150044250A1 (en) 2015-02-12
EP2807186A1 (en) 2014-12-03
US9388394B2 (en) 2016-07-12
EP2807186A4 (en) 2016-01-27
JP2015506948A (ja) 2015-03-05
MX2014009106A (es) 2014-11-10
RU2014134365A (ru) 2016-03-20
CN104039816A (zh) 2014-09-10
MX351074B (es) 2017-09-28
JP2017141226A (ja) 2017-08-17
AU2013211973A1 (en) 2014-06-12
WO2013112867A1 (en) 2013-08-01
BR112014018432A8 (pt) 2017-07-11
IN2014CN04187A (es) 2015-07-17
TW201335178A (zh) 2013-09-01

Similar Documents

Publication Publication Date Title
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
CL2018001053A1 (es) Vacuna contra el virus sincicial respiratorio
BR112018008090A2 (pt) vacina de vírus do herpes simplex.
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
MX2017012220A (es) Composiciones adyuvantes y metodos relacionados.
BR112016006326A2 (pt) formulação seca de uma vacina, uso de uma formulação seca, método para fabricação de uma formulação seca, e, vacina
CO6751260A2 (es) Vacunas basadas en omv contra infecciones por burkholderia
PE20151588A1 (es) Vacuna contra el virus del dengue
BR112016015422A2 (pt) formulações de vacina de frasco único
BR112014032636A2 (pt) Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas
EA201891124A2 (ru) Новые мукозные адъюванты и системы доставки
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
CO7461133A2 (es) Parvovirus 5a porcino, métodos de uso y vacuna
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
WO2015051371A3 (en) Haemophilus parasuis vaccine serovar type four
BR112015017903A2 (pt) vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
CO2018010359A2 (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
BR112017010883A2 (pt) composições adjuvantes e métodos relacionados
AR093530A1 (es) Adyuvante de vacunacion, preparacion, y vacunas que lo contienen
CU20110181A7 (es) Composición para el control de patógenos
UY36208A (es) “bacterias modificadas para vacunas mejoradas contra la brucelosis”.

Legal Events

Date Code Title Description
FB Suspension of granting procedure